FDA Schedules 2026 Public Meeting on Hemp Ingredient GRAS Determinations
The U.S. Food and Drug Administration has announced a public meeting scheduled for later this month to discuss Generally Recognized as Safe (GRAS) determinations for hemp-derived ingredients. The session will focus on pathways for companies seeking voluntary GRAS notifications for ingredients used in conventional foods.
Why This Matters for Industry
GRAS status provides a clearer route for hemp-derived ingredients to enter the food supply without requiring new dietary ingredient notifications. Industry groups have long called for standardized processes that reduce uncertainty around compliance. Participants are expected to include representatives from trade associations, ingredient suppliers, and academic researchers.
Meeting Details and Expected Outcomes
The meeting will be held virtually, with registration open through mid-June. Written comments will be accepted for 30 days following the event. Observers note that any resulting guidance could influence how state regulators align their own enforcement approaches.
According to the Federal Register notice, the agency intends to address data requirements, safety assessment frameworks, and labeling considerations. No specific timelines for new GRAS notifications have been released.
This development follows earlier FDA communications on labeling and occurs amid ongoing discussions about federal oversight of cannabinoid-containing products. Stakeholders will monitor whether the meeting produces additional clarity on submission formats or safety study expectations.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.